AOD-9604

What is AOD 9604?

AOD 9604 is a man-made peptide (a small protein) that was originally developed to help with weight loss. It is a modified piece of human growth hormone that was designed to help burn fat without affecting blood sugar or causing other side effects of growth hormone. However, it's very important to know that AOD 9604 is not approved by the FDA for any medical use. This means it has not been proven safe or effective by the government agency that regulates medications in the United States.

How Does It Work?

AOD 9604 is supposed to work by telling your fat cells to break down stored fat and stop making new fat. It targets fat tissue specifically, particularly around the belly area. The medication is given as a shot under the skin, usually once a day. When researchers tested this medication in clinical studies, they hoped it would help people lose weight, but the studies showed it didn't work significantly better than a placebo (sugar pill). Because of these disappointing results, the company stopped developing it as a medication.

What Should You Know Before Using It?

Since AOD 9604 is not FDA-approved, you should be very careful about using it. Some people get it from online sources, wellness clinics, or anti-aging centers, but these sources are not regulated, and you cannot be sure what you're actually getting. The medication has not been tested enough to know if it's safe for long-term use or what all the side effects might be. You should never use this medication if you are pregnant, breastfeeding, under 18 years old, or have cancer. Talk to your regular doctor before using any unapproved medication, even if someone else recommends it.

What Are the Side Effects?

Based on the limited studies that were done, the most common side effects are reactions where you inject the medication, such as redness, swelling, pain, or bruising. Some people also reported headaches, feeling tired, nausea, or dizziness. Because this medication hasn't been studied in large numbers of people or for long periods of time, there could be other side effects that we don't know about yet. If you experience severe allergic reactions like difficulty breathing, severe rash, or swelling of your face or throat, seek emergency medical help immediately.

Important Warnings

Remember that claims about AOD 9604 helping with weight loss, improving body composition, or providing anti-aging benefits are not proven by solid scientific evidence. The medication failed its clinical trials for weight loss. If you choose to use this unapproved medication, make sure you tell all your healthcare providers about it, use proper sterile technique when injecting to avoid infections, and watch carefully for any side effects. Your health and safety should always come first, and FDA-approved medications for weight loss have been tested much more thoroughly and may be safer and more effective options.

AOD 9604 (Advanced Obesity Drug 9604) is a synthetic peptide consisting of a modified fragment of the C-terminal region of human growth hormone. Developed in the 1990s by Professor Frank Ng at Monash University in Australia, the compound was specifically engineered to isolate the fat-metabolizing effects of growth hormone while eliminating unwanted side effects such as effects on blood sugar and cell proliferation. The peptide contains 15 amino acids with a tyrosine modification to improve its pharmacological properties.

The development of AOD 9604 was based on research demonstrating that the C-terminal fragment of hGH (amino acids 176-191) retained lipolytic activity. Metabolic Pharmaceuticals Ltd. conducted clinical trials in the early 2000s investigating AOD 9604 for obesity treatment. Despite initial promise in preclinical models, Phase II clinical trials failed to demonstrate statistically significant weight loss compared to placebo in obese subjects. Consequently, the compound was never approved by the FDA, European Medicines Agency (EMA), or Therapeutic Goods Administration (TGA) in Australia for any medical indication.

Following the unsuccessful clinical development program, AOD 9604 has appeared in unregulated markets, particularly in anti-aging clinics, wellness centers, and bodybuilding communities. It is sometimes marketed for weight loss, body composition improvement, and purported regenerative properties. The peptide is typically administered via subcutaneous injection, though oral formulations have been investigated. It is important to note that AOD 9604 is not approved for human use and is classified as a research chemical.

The regulatory status of AOD 9604 varies by jurisdiction. In the United States, it is not approved by the FDA and is not legally marketed as a drug or dietary supplement. The World Anti-Doping Agency (WADA) has classified growth hormone fragments, including AOD 9604, as prohibited substances in competitive sports. Healthcare providers should be aware that patients may obtain this compound through online sources or compounding pharmacies operating in regulatory gray areas.

Current interest in AOD 9604 persists primarily in research contexts exploring peptide-based therapies for metabolic disorders and tissue regeneration. However, the lack of robust clinical evidence, unclear safety profile, and absence of regulatory approval limit its legitimate therapeutic applications. Any clinical use would be considered off-label and experimental, requiring careful informed consent and monitoring.

AOD 9604 is a modified peptide fragment that mimics the lipolytic (fat-burning) region of human growth hormone without affecting insulin-like growth factor-1 (IGF-1) levels or glucose metabolism. The compound was designed to retain the fat-reducing effects of hGH while eliminating the growth-promoting and diabetogenic effects associated with full-length growth hormone.

At the molecular level, AOD 9604 is believed to stimulate lipolysis (the breakdown of fat) and inhibit lipogenesis (the formation of fatty acids and lipids) in adipose tissue. The proposed mechanism involves activation of beta-3 adrenergic receptors on adipocytes, leading to increased cyclic AMP (cAMP) production and subsequent activation of hormone-sensitive lipase. This enzymatic cascade promotes the hydrolysis of triglycerides into free fatty acids and glycerol, which can then be utilized for energy.

Unlike full-length growth hormone, AOD 9604 does not bind to growth hormone receptors with significant affinity, which theoretically reduces the risk of hyperglycemia, insulin resistance, and proliferative effects. The peptide's tyrosine residue at position 3 was modified to enhance stability and bioavailability. However, the exact receptor binding profile and complete signaling pathways remain incompletely characterized in human studies.

The peptide's effects on metabolism are thought to be tissue-specific, primarily targeting adipose tissue while sparing muscle tissue. Some preclinical studies have suggested additional effects on cartilage regeneration and anti-inflammatory properties, though these mechanisms are not well-established and require further investigation.

Important Notice

AOD 9604 is not FDA-approved for any medical indication. The following information is provided for educational purposes based on investigational protocols and does not constitute a recommendation for clinical use. Any administration of AOD 9604 would be considered experimental and off-label.

Investigational Dosing Protocols

Based on clinical trial data from discontinued development programs:

Subcutaneous Administration

Timing: Typically administered in the morning on an empty stomach, at least 30 minutes before food intake, based on trial protocols.

Injection Sites: Subcutaneous injection into abdominal adipose tissue was most commonly used in trials. Rotation of injection sites is recommended to minimize local reactions.

Reconstitution and Preparation

AOD 9604 is typically supplied as a lyophilized powder requiring reconstitution:

1. Use bacteriostatic water or sterile water for injection

2. Add diluent slowly along the side of the vial to avoid foaming

3. Gently swirl (do not shake vigorously) until powder is completely dissolved

4. Typical reconstitution: 2 mg powder with 2 mL bacteriostatic water = 1 mg/mL concentration

5. Store reconstituted solution refrigerated (2-8°C) and use within 14 days

Duration of Treatment

Clinical trials typically evaluated treatment durations of 12 weeks. Optimal treatment duration has not been established, and long-term safety data beyond 12 weeks is not available.

Special Populations

Renal Impairment

No specific dosing adjustments have been established. Given renal elimination of peptide fragments, caution and potential dose reduction may be warranted in moderate to severe renal impairment, though data is insufficient to provide specific recommendations.

Hepatic Impairment

No specific dosing adjustments established. Hepatic metabolism is not a primary elimination pathway for this peptide.

Geriatric Patients

No specific dosing adjustments established. Elderly patients were not specifically studied in clinical trials.

Pediatric Patients

Safety and efficacy have not been established in pediatric populations. Use in children is not recommended.

Pregnancy and Lactation

No data available. Use is contraindicated in pregnancy and lactation due to lack of safety data.

Administration Instructions

• Inspect reconstituted solution for particulate matter and discoloration before administration

• Use appropriate sterile technique for subcutaneous injection

• Inject slowly over 5-10 seconds

• Dispose of needles and syringes in appropriate sharps containers

• Do not share injection equipment between patients

Monitoring

No established monitoring parameters exist due to investigational status. If used experimentally, consider monitoring:

• Body weight and composition

• Metabolic parameters (glucose, lipids)

• Injection site reactions

• Adverse events

Storage

• Lyophilized powder: Store at 2-8°C (refrigerated), protect from light

• Reconstituted solution: Store at 2-8°C, use within 14 days

• Do not freeze

• Keep out of reach of children

The clinical evidence base for AOD 9604 is limited and primarily consists of early-phase trials conducted in the early 2000s. The most significant clinical investigation was a randomized, double-blind, placebo-controlled Phase II trial conducted by Metabolic Pharmaceuticals in obese adults. This 12-week study enrolled approximately 300 participants with body mass index (BMI) between 30-40 kg/m². Subjects received daily subcutaneous injections of AOD 9604 at doses ranging from 1 mg to 10 mg, or placebo. The primary endpoint was change in body weight and body composition measured by DEXA scan.

Results from this pivotal trial were disappointing and ultimately led to discontinuation of the clinical development program. While some secondary analyses suggested modest reductions in abdominal fat in certain subgroups, the primary endpoint of statistically significant weight loss compared to placebo was not achieved. Mean weight loss in the highest dose group (10 mg daily) was approximately 1.2 kg compared to 0.8 kg in the placebo group over 12 weeks, a difference that was not statistically significant. Body composition changes, including fat mass reduction, similarly failed to reach statistical significance in the intention-to-treat analysis.

Earlier Phase I studies established basic safety and tolerability in healthy volunteers, with doses up to 10 mg daily administered for short durations (up to 4 weeks) without serious adverse events. These studies confirmed that AOD 9604 did not significantly affect glucose metabolism, insulin levels, or IGF-1 concentrations, supporting its selectivity for lipolytic effects. However, the lack of robust efficacy in Phase II trials prevented advancement to Phase III development.

Since the discontinuation of formal clinical development, there have been no large-scale, peer-reviewed clinical trials published on AOD 9604. Anecdotal reports and small observational studies in wellness and anti-aging contexts lack scientific rigor, proper controls, and peer review. Some preclinical studies have explored potential applications in cartilage repair and osteoarthritis, showing modest effects in animal models, but these findings have not been validated in human trials.

The absence of FDA approval and limited clinical evidence base means that AOD 9604 lacks established efficacy for any medical indication. Healthcare providers should counsel patients that claims regarding weight loss, body composition improvement, or regenerative effects are not supported by high-quality clinical evidence. The compound remains investigational, and any use occurs outside the framework of evidence-based medicine.

Critical Safety Notice

The safety profile of AOD 9604 is incompletely characterized due to limited clinical trial data and lack of post-marketing surveillance. The compound is not FDA-approved, and comprehensive safety information is not available. Healthcare providers and patients should exercise extreme caution, as long-term safety, rare adverse events, and interactions remain unknown.

Contraindications

Absolute Contraindications

• Known hypersensitivity: Patients with known hypersensitivity to AOD 9604 or any component of the formulation should not use this compound

• Active malignancy: Due to theoretical concerns about peptide effects on cell proliferation, use in patients with active cancer is contraindicated

• Pregnancy: No safety data exists for use during pregnancy; potential risks to fetal development are unknown

• Lactation: Unknown whether AOD 9604 is excreted in breast milk; use during breastfeeding is contraindicated

• Pediatric patients: Safety and efficacy not established in children under 18 years

Relative Contraindications and Precautions

• Severe renal impairment: Altered clearance may occur; use with caution if at all

• History of peptide allergies: Increased risk of hypersensitivity reactions

• Diabetes mellitus: Although AOD 9604 was designed not to affect glucose metabolism, monitoring is prudent

• Cardiovascular disease: Limited safety data in patients with significant cardiovascular conditions

• Autoimmune disorders: Theoretical immunogenic potential of peptide compounds

Adverse Effects

Common Adverse Effects (reported in clinical trials)

Based on limited Phase I and II trial data, the following adverse effects were reported:

Injection Site Reactions (10-20% of subjects):

• Erythema, swelling, or irritation at injection site

• Mild pain or discomfort

• Bruising

• Usually self-limiting and resolving within 24-48 hours

Systemic Effects (5-15% of subjects):

• Headache

• Fatigue or lethargy

• Nausea

• Dizziness

• Flu-like symptoms

Metabolic Effects:

• No significant effects on glucose metabolism were observed in trials

• Lipid profile changes were inconsistent and not clinically significant

Serious Adverse Effects

No serious adverse events were definitively attributed to AOD 9604 in published trial data. However, the limited sample size and duration of studies mean that rare serious adverse events may not have been detected.

Potential Serious Risks (theoretical or based on peptide class effects):

• Severe allergic reactions: Anaphylaxis or severe hypersensitivity reactions possible with any peptide compound

• Immunogenicity: Development of antibodies against the peptide with repeated administration

• Injection site infections: Risk with any injectable medication, particularly with improper technique

• Tumor promotion: Theoretical concern with any growth hormone-related compound, though not observed in limited trials

Special Populations

Pregnancy (Category: Not Established)

No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Potential risks to fetal development are unknown. Use is contraindicated in pregnancy.

Lactation

It is unknown whether AOD 9604 is excreted in human milk. Due to lack of data and potential for adverse effects in nursing infants, use is contraindicated during breastfeeding.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established. Growth and development effects are unknown. Not recommended for use in patients under 18 years.

Geriatric Use

Clinical trials did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently than younger subjects. Age-related renal impairment may affect clearance.

Renal Impairment

Peptide fragments are eliminated renally. Patients with moderate to severe renal impairment may experience reduced clearance and increased exposure. No specific dosing recommendations exist due to insufficient data.

Hepatic Impairment

Hepatic metabolism is not a primary elimination pathway. No specific precautions established, though data is limited.

Monitoring Parameters

Due to investigational status, no standardized monitoring protocols exist. If used experimentally, consider:

• Baseline and periodic assessments:

  • Complete metabolic panel (glucose, electrolytes, renal function)

  • Lipid profile

  • Body weight and composition

  • Vital signs

• Injection site monitoring: Assess for signs of infection, persistent irritation, or tissue changes

• Adverse event monitoring: Systematic assessment and documentation of any adverse effects

• Antibody formation: Consider testing for anti-drug antibodies with prolonged use (specialized testing)

Overdose

No cases of overdose have been reported in the literature. Management would be supportive and symptomatic. There is no specific antidote. In case of suspected overdose, contact poison control and provide supportive care.

Drug Interactions

Comprehensive drug interaction studies have not been conducted. Potential interactions include:

• Lipid-modifying agents: Theoretical additive effects on lipid metabolism

• Antidiabetic medications: Monitor glucose levels, though significant interactions not expected based on mechanism

• Other peptide hormones: Concurrent use not studied; potential for unpredictable interactions

• Immunosuppressants: May affect immunogenic response to peptide

Patient Counseling Points

• This compound is not FDA-approved for any medical use

• Efficacy for weight loss or body composition has not been proven in rigorous trials

• Report any injection site reactions that worsen or do not resolve

• Seek immediate medical attention for signs of severe allergic reaction (difficulty breathing, severe rash, swelling of face or throat)

• Use proper sterile injection technique to minimize infection risk

• Store properly and dispose of needles safely

• Inform all healthcare providers about use of this investigational compound

Pharmacokinetics

The pharmacokinetic profile of AOD 9604 has been characterized primarily through preclinical studies and limited human pharmacokinetic investigations. Following subcutaneous administration, the peptide demonstrates relatively rapid absorption with peak plasma concentrations typically achieved within 30-60 minutes. The bioavailability via subcutaneous injection is estimated to be approximately 50-80%, though precise values vary across studies. Oral bioavailability is significantly lower due to peptide degradation in the gastrointestinal tract and first-pass metabolism, though some modified formulations have attempted to improve oral absorption.

The distribution of AOD 9604 appears to be primarily extracellular, with limited tissue penetration beyond adipose tissue, which is the primary target site. The volume of distribution has not been precisely characterized in humans but is estimated to be moderate based on the peptide's molecular weight (approximately 1.8 kDa) and hydrophilic properties. Protein binding data for AOD 9604 is limited, but as a small peptide, it likely exhibits minimal binding to plasma proteins, existing primarily in the free, pharmacologically active form.

Metabolism of AOD 9604 occurs primarily through peptidase-mediated hydrolysis, similar to other peptide compounds. The peptide is broken down into constituent amino acids by proteolytic enzymes in plasma and tissues. The elimination half-life is relatively short, estimated at 2-4 hours following subcutaneous administration, necessitating frequent dosing to maintain therapeutic levels. Elimination occurs primarily through renal excretion of metabolites and intact peptide fragments, with some biliary excretion. Patients with significant renal impairment may experience altered clearance, though specific dosing adjustments have not been established due to limited clinical data.

Pharmacodynamics

The pharmacodynamic effects of AOD 9604 are characterized by its selective action on lipid metabolism. In preclinical models, the peptide demonstrated dose-dependent increases in lipolysis, with effects observable at concentrations as low as 10^-9 M in isolated adipocyte preparations. The onset of metabolic effects following administration occurs within hours, with peak lipolytic activity corresponding to peak plasma concentrations. The duration of action extends beyond the plasma half-life, suggesting tissue accumulation or persistent receptor activation.

Importantly, AOD 9604 does not appear to significantly affect glucose metabolism, insulin sensitivity, or IGF-1 levels at doses studied in clinical trials, distinguishing it from full-length growth hormone. This selectivity was a primary design goal but also contributed to questions about its overall metabolic efficacy. The peptide does not stimulate cell proliferation or demonstrate mitogenic effects in standard assays, reducing theoretical concerns about tumor promotion.

Drug Interactions

Due to limited clinical use and investigation, comprehensive drug-drug interaction data for AOD 9604 is sparse. As a peptide that does not undergo cytochrome P450 metabolism, traditional drug metabolism interactions are unlikely. However, theoretical interactions could occur with medications affecting lipid metabolism, including fibrates, statins, and other lipid-modifying agents, potentially leading to additive effects or altered lipid profiles. Concurrent use with other peptide hormones or growth hormone secretagogues has not been systematically studied. Patients using medications that affect renal function may experience altered clearance of AOD 9604, though clinical significance is unknown.